Needham analyst David Saxon has maintained their neutral stance on SGHT stock, giving a Hold rating today.
David Saxon’s rating is based on a combination of factors including Sight Sciences’ revenue performance and future outlook. The company’s fourth-quarter revenue for 2024 met expectations, aligning with its prior announcements. However, the guidance for 2025 revenue was set below market consensus, primarily due to anticipated challenges in the volume outlook for OMNI, influenced by LCD impacts, and assumptions of stable revenue from Dry Eye treatments despite ongoing reimbursement efforts.
Additionally, while there is progress in the submission and reimbursement of TearCare claims, with some payors providing more consistent payouts, the process has not yet reached a standardized level. These elements contribute to a balanced risk/reward scenario, leading to the decision to maintain a Hold rating on the stock.
In another report released today, Morgan Stanley also maintained a Hold rating on the stock with a $3.00 price target.
Based on the recent corporate insider activity of 42 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SGHT in relation to earlier this year.